フィルター
81 件の結果が “930” で取得されました
並べ替える:
アルファベット順（A-Z）
ベストセラー
huCD19
製品ID :
C001731
系統:
C57BL/6NCya
状況:
説明:
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [1]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [2]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [3].
The huCD19 mouse is a humanized model generated using gene editing technology by replacing the sequence from the ATG start codon to part of intron 4 in the endogenous murine Cd19 gene with the corresponding human CD19 gene sequence. This model is applicable for studying B cell development and function, as well as therapeutic research on autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and B cell malignancies. It is an ideal research platform for preclinical efficacy evaluation of anti-human CD19 CAR-T cell therapy, and the development of bispecific antibodies and combination therapies.
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [1]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [2]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [3].
The huCD19 mouse is a humanized model generated using gene editing technology by replacing the sequence from the ATG start codon to part of intron 4 in the endogenous murine Cd19 gene with the corresponding human CD19 gene sequence. This model is applicable for studying B cell development and function, as well as therapeutic research on autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and B cell malignancies. It is an ideal research platform for preclinical efficacy evaluation of anti-human CD19 CAR-T cell therapy, and the development of bispecific antibodies and combination therapies.
huCD19(2)
製品ID :
C002032
系統:
C57BL/6NCya
状況:
説明:
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [1]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [2]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [3].
The huCD19(2) mouse is a humanized model generated using gene editing technology by replacing the sequence from the start codon to the stop codon in the endogenous murine Cd19 gene with the corresponding sequence of human CD19. This model is applicable for studying B cell development and function, as well as therapeutic research on autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and B cell malignancies. It is an ideal research platform for preclinical efficacy evaluation of anti-human CD19 CAR-T cell therapy and the development of bispecific antibodies and combination therapies.
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [1]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [2]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [3].
The huCD19(2) mouse is a humanized model generated using gene editing technology by replacing the sequence from the start codon to the stop codon in the endogenous murine Cd19 gene with the corresponding sequence of human CD19. This model is applicable for studying B cell development and function, as well as therapeutic research on autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), and B cell malignancies. It is an ideal research platform for preclinical efficacy evaluation of anti-human CD19 CAR-T cell therapy and the development of bispecific antibodies and combination therapies.
B6-huEPCAM
製品ID :
C001930
系統:
C57BL/6JCya
状況:
説明:
The EPCAM gene encodes a transmembrane glycoprotein, Epithelial Cell Adhesion Molecule (EPCAM), also known as CD326 or Trop-1, which mediates calcium-independent homotypic cell adhesion and participates in fundamental processes including cell adhesion, migration, proliferation, and signal transduction, thereby maintaining epithelial tissue integrity [1]. While normally expressed on the surface of epithelial cells in organs such as the gastrointestinal tract, lungs, and skin, EPCAM is frequently overexpressed in various cancers, including colorectal, breast, and pancreatic carcinomas, but is largely absent or weakly expressed in healthy squamous epithelia [1]. Structurally, EPCAM comprises an extracellular domain (EpEX) mediating intercellular adhesion, a transmembrane domain, and a short intracellular domain (EpICD). Upon proteolytic cleavage by ADAM17 and γ-secretase, EpICD translocates to the nucleus, activating oncogenic pathways such as Wnt/β-catenin, ERK, and FAK-AKT, which promotes epithelial-mesenchymal transition (EMT), tumor progression, and metastasis [2]. Notably, EPCAM serves as a marker for circulating tumor cells (CTCs) and cancer stem cells, and its downregulation during EMT can complicate advanced cancer detection [2-3]. Furthermore, dysregulated EPCAM expression is associated with congenital tufting enteropathy (CTE), a severe intestinal epithelial dysfunction [2]. Given its involvement in tumor metastasis through interaction with HGFR (c-Met), targeting EPCAM with strategies like the neutralizing antibody EpAb2-6 in combination with HGFR inhibitors has shown promising preclinical efficacy [4].
The B6-huEPCAM mouse is a humanized model constructed through gene-editing technology, in which the mouse Epcam extracellular domain is replaced with the human EPCAM extracellular domain. This model can be used for research on tumor mechanisms and tumor immunotherapy, as well as for the development of EPCAM-targeted drugs.
The EPCAM gene encodes a transmembrane glycoprotein, Epithelial Cell Adhesion Molecule (EPCAM), also known as CD326 or Trop-1, which mediates calcium-independent homotypic cell adhesion and participates in fundamental processes including cell adhesion, migration, proliferation, and signal transduction, thereby maintaining epithelial tissue integrity [1]. While normally expressed on the surface of epithelial cells in organs such as the gastrointestinal tract, lungs, and skin, EPCAM is frequently overexpressed in various cancers, including colorectal, breast, and pancreatic carcinomas, but is largely absent or weakly expressed in healthy squamous epithelia [1]. Structurally, EPCAM comprises an extracellular domain (EpEX) mediating intercellular adhesion, a transmembrane domain, and a short intracellular domain (EpICD). Upon proteolytic cleavage by ADAM17 and γ-secretase, EpICD translocates to the nucleus, activating oncogenic pathways such as Wnt/β-catenin, ERK, and FAK-AKT, which promotes epithelial-mesenchymal transition (EMT), tumor progression, and metastasis [2]. Notably, EPCAM serves as a marker for circulating tumor cells (CTCs) and cancer stem cells, and its downregulation during EMT can complicate advanced cancer detection [2-3]. Furthermore, dysregulated EPCAM expression is associated with congenital tufting enteropathy (CTE), a severe intestinal epithelial dysfunction [2]. Given its involvement in tumor metastasis through interaction with HGFR (c-Met), targeting EPCAM with strategies like the neutralizing antibody EpAb2-6 in combination with HGFR inhibitors has shown promising preclinical efficacy [4].
The B6-huEPCAM mouse is a humanized model constructed through gene-editing technology, in which the mouse Epcam extracellular domain is replaced with the human EPCAM extracellular domain. This model can be used for research on tumor mechanisms and tumor immunotherapy, as well as for the development of EPCAM-targeted drugs.
huPD-1/huCD19
製品ID :
C002040
系統:
C57BL/6J;6NCya
状況:
説明:
The huPD-1/huCD19 mouse is a dual-gene humanized model obtained by crossing the huPD-1 mouse (Catalog No.: C001524) with the huCD19 mouse (Catalog No.: C001731). This model is suitable for studying drug screening, pharmacodynamic evaluation, safety assessment, tumor immunotherapy, and the underlying mechanisms of the immune system related to PD-1/CD19.
The huPD-1/huCD19 mouse is a dual-gene humanized model obtained by crossing the huPD-1 mouse (Catalog No.: C001524) with the huCD19 mouse (Catalog No.: C001731). This model is suitable for studying drug screening, pharmacodynamic evaluation, safety assessment, tumor immunotherapy, and the underlying mechanisms of the immune system related to PD-1/CD19.
huCD19/huCD3
製品ID :
C001851
系統:
C57BL/6NCya
状況:
説明:
Cluster of differentiation 3 (CD3) is a multimeric protein complex that is essential for T cell activation and antigen recognition. It consists of five different polypeptide chains (γ, δ, ε, ζ, and η) that are noncovalently associated with the T cell receptor (TCR). The TCR is responsible for recognizing antigens presented by antigen-presenting cells (APCs), while CD3 transduces the activation signal into the T cell and activates helper T-cells and cytotoxic T-cells [1-2]. The CD3-TCR complex is expressed on the surface of all mature T cells, and its assembly is required for T cell development and function. CD3 plays a crucial role in stabilizing the TCR and facilitating its interaction with antigens. It also recruits signaling molecules to the TCR, which initiates a cascade of events that leads to T cell activation. CD3 is a highly specific T cell marker, and its expression is increased upon T cell activation. This makes it a valuable tool for identifying and characterizing T cells in tissues and blood samples. CD3 staining is also used to diagnose T-cell lymphomas and leukemias. Due to its essential role in T cell activation, CD3 is a promising target for immunosuppressive therapy. Several anti-CD3 monoclonal antibodies have been developed and are being tested in clinical trials for the treatment of autoimmune diseases, such as type 1 diabetes and rheumatoid arthritis [3].
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [4]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B-cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [5]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [6].
huCD19/huCD3 mouse is a dual-gene humanized model generated by crossing huCD3 mice (Catalog No.: C001325) with huCD19 mice (Catalog No.: C001731). This strain is applicable for the development, validation, and preclinical evaluation of bispecific antibodies targeting human CD3/CD19, as well as for research on malignant tumors such as B-cell lymphoma and immunosuppressive therapies for autoimmune diseases. It serves as an ideal platform for the development of combination therapies.
Cluster of differentiation 3 (CD3) is a multimeric protein complex that is essential for T cell activation and antigen recognition. It consists of five different polypeptide chains (γ, δ, ε, ζ, and η) that are noncovalently associated with the T cell receptor (TCR). The TCR is responsible for recognizing antigens presented by antigen-presenting cells (APCs), while CD3 transduces the activation signal into the T cell and activates helper T-cells and cytotoxic T-cells [1-2]. The CD3-TCR complex is expressed on the surface of all mature T cells, and its assembly is required for T cell development and function. CD3 plays a crucial role in stabilizing the TCR and facilitating its interaction with antigens. It also recruits signaling molecules to the TCR, which initiates a cascade of events that leads to T cell activation. CD3 is a highly specific T cell marker, and its expression is increased upon T cell activation. This makes it a valuable tool for identifying and characterizing T cells in tissues and blood samples. CD3 staining is also used to diagnose T-cell lymphomas and leukemias. Due to its essential role in T cell activation, CD3 is a promising target for immunosuppressive therapy. Several anti-CD3 monoclonal antibodies have been developed and are being tested in clinical trials for the treatment of autoimmune diseases, such as type 1 diabetes and rheumatoid arthritis [3].
The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B cell receptor (BCR) signaling pathway, it is crucial for B cell development, activation, and differentiation. CD19, a pan-B-cell marker exclusively expressed in the B cell lineage, remains stable throughout B cell development, from pro-B cells to mature and memory B cells. It acts as a positive regulator of BCR signal transduction by forming a B cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B cell activation [4]. Dysregulation of CD19 is strongly linked to autoimmune diseases such as systemic lupus erythematosus (SLE) and B cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), characterized by impaired B cell differentiation and hypogammaglobulinemia. Owing to its B-cell-specific expression, CD19 has become a pivotal target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., Tisagenlecleucel) has shown remarkable efficacy in refractory or relapsed ALL [5]. Recent studies have also explored CD19-targeted bispecific antibodies (e.g., blinatumomab) to enhance tumor cell clearance [6].
huCD19/huCD3 mouse is a dual-gene humanized model generated by crossing huCD3 mice (Catalog No.: C001325) with huCD19 mice (Catalog No.: C001731). This strain is applicable for the development, validation, and preclinical evaluation of bispecific antibodies targeting human CD3/CD19, as well as for research on malignant tumors such as B-cell lymphoma and immunosuppressive therapies for autoimmune diseases. It serves as an ideal platform for the development of combination therapies.
Gpr182-KO
製品ID :
S-KO-00930
系統:
C57BL/6JCya
状況:
説明:
Gpr182 is located on chromosome 10 of mice. Nuclease Technology was used to design sgRNA; Gpr182 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Gpr182 is located on chromosome 10 of mice. Nuclease Technology was used to design sgRNA; Gpr182 knockout mice were obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
huCD19/huBCMA
製品ID :
C001993
系統:
C57BL/6NCya
状況:
説明:
CD19 is predominantly expressed throughout B-cell development and serves as a critical co-receptor for B-cell receptor (BCR) signal transduction, participating in B-cell development, activation, and differentiation [1]. The TNFRSF17 gene encodes B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily. BCMA is primarily expressed on mature B cells and plasma cells and acts as a key regulator for maintaining plasma cell survival, antibody secretion, and humoral immunity [2-3].
The huCD19/huBCMA(TNFRSF17) mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630). These two targets cover the critical stages of B-cell development and plasma cell maturation, respectively, together forming an important regulatory network for B-cell immune responses. This model can be used to study the mechanisms of B-cell development, differentiation, and humoral immunity regulation, as well as B-cell-related autoimmune diseases and malignancies, such as systemic lupus erythematosus (SLE) and multiple myeloma (MM). It is also suitable for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of anti-CD19 and anti-BCMA dual-target drugs, CAR-T cell therapies, bispecific antibodies, and combination treatment strategies, providing an ideal preclinical research platform for the development of innovative therapies for B-cell-related diseases.
CD19 is predominantly expressed throughout B-cell development and serves as a critical co-receptor for B-cell receptor (BCR) signal transduction, participating in B-cell development, activation, and differentiation [1]. The TNFRSF17 gene encodes B-cell maturation antigen (BCMA), a member of the tumor necrosis factor receptor superfamily. BCMA is primarily expressed on mature B cells and plasma cells and acts as a key regulator for maintaining plasma cell survival, antibody secretion, and humoral immunity [2-3].
The huCD19/huBCMA(TNFRSF17) mouse is a dual-gene humanized model obtained by crossing the huCD19 mouse (Catalog No.: C001731) with the huBCMA(TNFRSF17) mouse (Catalog No.: C001630). These two targets cover the critical stages of B-cell development and plasma cell maturation, respectively, together forming an important regulatory network for B-cell immune responses. This model can be used to study the mechanisms of B-cell development, differentiation, and humoral immunity regulation, as well as B-cell-related autoimmune diseases and malignancies, such as systemic lupus erythematosus (SLE) and multiple myeloma (MM). It is also suitable for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of anti-CD19 and anti-BCMA dual-target drugs, CAR-T cell therapies, bispecific antibodies, and combination treatment strategies, providing an ideal preclinical research platform for the development of innovative therapies for B-cell-related diseases.
Aatk-flox
製品ID :
S-CKO-00930
系統:
C57BL/6JCya
状況:
説明:
Aatk is located on chromosome 11 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Aatk conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Aatk is located on chromosome 11 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Aatk conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Zfp930-KO
製品ID :
S-KO-06702
系統:
C57BL/6JCya
状況:
説明:
Zfp930 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp930 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp930 is located on chromosome 8 of mice. Nuclease Technology will be used to design sgRNA; Zfp930 knockout mice will be obtained by applying high-throughput electroporation of fertilized eggs. After sexual maturity, sperm were collected for cryopreservation.
Zfp930-flox
製品ID :
S-CKO-07725
系統:
C57BL/6JCya
状況:
説明:
Zfp930 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp930 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Zfp930 is located on chromosome 8 of mice. SgRNA and ssDNA will be designed using Nuclease Technology; Zfp930 conditional knockout mice will be obtained by high-throughput electroporation of fertilized eggs. After sexual maturity, sperm will be collected for cryopreservation.
Items: 1 to 10 of 81
1
2
3
4
5
6
7
8
9
さらに